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Supplementary Figure 1: drl reporter-expressing cells contribute to mesendoderm with LPM-restricted mesoderm contribution 
(a) Schematic representation of drl:creERT2, sox17:creERT2, and ubi:creERT2 crosses to hsp70l:Switch for genetic lineage tracing. (b-d) Whole-body 
representative transverse sections of lineage traced embryos at 72 hpf following different 4-OHT induction time points (shield, tailbud, 1-2 ss, and 5-6 ss) to 
trigger hsp70l:Switch recombination (green), nuclei counterstained with DAPI (blue). Numbers indicate the percentage of embryos showing lineage-labeling 
in depicted organs. (b) drl:creERT2 with 4-OHT induction at shield stage traces, besides of LPM-derived tissue, a high percentage of endoderm-derived 
lineages, as depicted for liver (li), swim bladder (sb), pancreas (pa), and gut (g), while 4-OHT induction at 5-6 ss traces shows reduced to minimal lineage 
labeling in endoderm-derived tissue. (c) Transverse sections of sox17:creERT2 lineage-traced endoderm cells after 4-OHT induction at shield stage. 
Lineage labeling is confined to endodermal lineages and absent from mesodermal and specifically LPM lineages, as depicted for the pharynx, pancreas, 
gut, and liver, in contrast to LPM-derived tissue such as the aorta (arrow). (d) No tissue bias or obvious absence of EGFP in lineage reporter labeling could 
be detected for the hsp70l:Switch line, as shown using the ubiquitous ubi:creERT2. Scale bar 50 μm. 
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Supplementary Figure 2
Supplementary Figure 2: The LPM specifies within the mesendoderm with a temporal and an anterior-posterior gradient 
(a) Schematic of the four regions I-IV defined to study anterior-posterior differences in lineage-labeling of the gut epithelium. Region I is the most rostral and 
includes the pharynx and the heart; Region II inlcudes the esophagus, the beginning of the swim bladder (pneumatic duct), the liver, and the anterior tip of 
the pancreas; Region III includes the gut, pancreas, and swim bladder; region IV includes the most caudal part of the gut and is recognizable by the yolk 
extension. (b) Transverse sections of the gut of 3 dpf drl:creERT2;hsp70l:Switch embryos. Columns represent the region and rows represent the stage of 4-
OHT induction. (C) For each section, the switching efficiency in the gut epithelium was classified into 0%, between 0-33%, between 33-66% or between 66-
100%. The Y-axis represents the fraction number of embryos. Indicated n-numbers represent the number of embryos analyzed. Embryos were collected in 
three independent experiments. Scale bar 25 μm. 
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Supplementary Figure 3
Supplementary Figure 3: LPM lineages and organs still arise in embryos devoid of endoderm  
Representative transverse sections of drl:creERT2 x ubi:Switch (ubi:lox-GFP-lox_mCherry) embryos fixed at 3 dpf. (a,b) Embryos were induced with 4-OHT 
at shield stage, bringing mCherry under control of the ubi promoter in cells with active CreERT2 from shield stage (magenta), while unrecombined cells keep 
expressing GFP (green). LPM-derived organs, as depicted for heart, blood, pectoral fins, pronephros, and endothelial cells, and endoderm-derived lineages, 
including swim bladder, gut epithelium, and liver, are lineage-traced (n=5/5). (c,d) In sox32 morphants that are devoid of endoderm, 4-OHT induction at 
shield stage still traced LPM-derived organs, as depicted for heart, blood, pectoral fins, pronephros (arrow), and endothelial cells (n=11/11). (e,f) Control 
without 4-OHT admission reveals absence of any background activity of the used ubi:Switch reporter (note autofluoresence of blood), confirming absence of 
leakiness of the creERT and loxP lines used (n=5/5). Asterisks indicate endoderm-derived gut epithelium (b,f) or absence thereof (d). Nuclei counterstained 
with DAPI (blue). Scale bar 25 μm. 
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Supplementary Figure 4
Supplementary Figure 4: Trimming of +2.0drl to the minimal 432 bp LPM +2.4drl enhancer region 
(a) Schematic representation of the -6.35drl locus including the PCR-based trimming approach to map the smallest LPM specific regulatory enhancer 
region; repetitive elements highlighted in blue. Sequence depicts the +2.0drl region in intron 1 (Danio rerio strain Tuebingen chromosome 5, GRCz11 
primary assembly, NC_007116.7:61649227-61650194): blue text depicts repetitive elements, colored boxes depict predicted transcription factor binding 
sites (JASPAR database for vertebrates, 80-85% threshold), yellow frame marks the beginning of drl exon 2, and red brackets outline the sequence for the 
+2.4drl core sequence. (b) Expression of +2.4drl:EGFP at 5 ss; arrow indicates axial mesoderm expression, indicating increased promiscuity after trimming 
from the initial +2.0drl element. Scale bar 400 μm (b) and 80 μm (c). 
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Supplementary Figure 5
Supplementary Figure 5: Response of endogenous drl and drl reporters to EomesA, Foxh1, and Mixl1 expression 
(a) Schematics of EomesA, Foxh1, and Mixl1 fusion proteins with the N-terminally added VP16 transactivation domain to generate constitutively-active 
transcription factors. Note that the expressed VP16-EomesA is restricted to the T-box of EomesA. (b-d) mRNA ISH for endogenous drl expression in 
controls (n=35/35) (b) and embryos injected with VP16-fusions based on eomesA (n=14/14) (c) or foxh1 (n=13/30) (d). (e,f) mRNA ISH for EGFP transcript 
expression in +2.0drl:EGFP embryos at shield to 70% epiboly stage after injecting a combination of VP16-fused eomesA and foxh1 (e/f) without (n=19/20) 
(e) or with (n=10/17) (f) constitutive-active smad2 that mimicks pan-Smad signaling (smad2(ca)), resulting in dorsal widening of the reporter expression 
pattern. (g) Injection of Tol2-based constructs under ubiquitous ubi promoter control to drive native eomesA (full-length), foxh1, and mixl1 (e/f/m), resulting 
in mosaic induction of +2.0drl:EGFP, including individual dorsal blastomeres (n=32/45). (h-j) Endogenous drl expression revealed by mRNA ISH in BMP 
signaling-mutant (MZsbn) embryos injected with either (h) VP16-e/f/m mRNA (n=32/42), (i) ubi:e/f/m DNA vectors (n=16/20), or (j) VP16-e/f/m mRNA in an 
endoderm-perturbed background (sox32 morpholino) (n=28/36). (k,l) mRNA ISH for endogenous drl expression in Nodal-mutant (MZoep) embryos injected 
with (k) VP16-e/f/m mRNA (16/24) or (l) ubi:e/f/m Tol2 vectors (17/28); note the localized clones of strong drl upregulation on the ventral side upon ubi:e/f/m 
injection. Scale bar 250 μm. 
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Supplementary Figure 6
Supplementary Figure 6: Crispant analysis of the +2.0drl region 
(a) Schematic representation of the minimal +2.4drl LPM enhancer region (core of +2.0drl) with Eomes, FoxH1, and Mixl1 binding site predictions (JASPAR) 
and sgRNAs ccG and ccH annotated. (b-i) ISH for EGFP in +2.0drl:EGFP embryos shown for injection controls (b-d) or individually mutagenized using 
reconstituted Cas9 protein-sgRNA complexes with either sgRNA (e-g) ccG or (h,i) ccH (asterisks in a), both showing mosaic loss or reduction of reporter 
expression at shield and bud stage compared to uninjected controls. Reporter expression that is dependent on different regulatory elements remains intact 
upon mutagenesis with both sgRNAs, as observed at 16 ss (d,g). These results indicate no overt mutagenesis of essential parts in the transgene itself. (j) 
Panel plot showing mutagenesis efficiency and allele spectrum in three representative ccH crispants, as created by CrispRVariants. The genomic reference 
sequence is shown on top, with the 20 bp ccH sgRNA followed by a 3 bp PAM indicated by the boxed regions. The Cas9 cleavage site is represented by a 
black vertical bar. Deletions are indicated by a minus (-) and insertion sequences by symbols. The right column of the plot shows detected allele frequency 
per analyzed embryo. Scale bar (b) 250 μm. 
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Supplementary Figure 7
Supplementary Figure 7: Effects of eomesA, foxh1, and mixl1 misexpression on early developmental genes 
(a-m) Zebrafish embryos ((a-l) shield to 75% epiboly or (m) 2 ss) as control or injected with mRNA for eomesA, foxh1, and mixl1 (e/f/m), with mRNA ISH for 
indicated candidate genes. Latera view left, animal view right for each condition. (a,b) The early LPM gene tmem88a that is weakly expressed during 
epiboly (a) becomes activated in patches upon e/f/m misexpression (b, arrowheads). (c-j) Expression of various gastrulation-stage marker genes: admp 
(c,d), sizzled (slightly increased expression ventral, indicated by arrowhead) (e,f), ved (slight increased expression ventral, arrow) (g,h), gata2a (slight 
ventral expansion) (i,j). (k-m) The somite-stage LPM gene hand2 does not become ectopically induced upon e/f/m misexpression (k-l), as tested with a 
functional mRNA ISH probe (shown for 2 ss in m). Indicated n-numbers represent the number of embryos analyzed. Scale bar (a) 250 μm. 
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Supplementary Figure 8: Mouse LPM enhancers show specific activity in chick, but not in zebrafish embryos 
(a) Bright field image of an HH10 stage chicken embryo, anterior to the left, with schematic depiction of the posterior body (right), prospective LPM in green. 
(b-d) Ex ovo-cultured chicken embryos at HH9-HH10, electroporated at HH3+/H4 with reporters based on mouse LPM enhancers from mGata4 (n=21/24) 
(b), mBmp4 (n=14/20) (c), and mHoxb6 (n=6/6) (d) driving EGFP (grayscale), including a merged overlay together with electroporation marker plasmid 
pCAGGS:RFP (magenta, driving ubiquitous expression as electroporation control). Dashed lines (b-d) indicate the posterior outline of the individual chicken 
embryos, marking the predicted boundary between embryo and extra-embryonic tissue. (e-h) Zebrafish embryos depicted at early somitogenesis stages 
(dorsal views in e-g, lateral view in h) injected with EGFP reporters for mBmp4 (n=12/52) (e), mGata4 (n=18/103) (f), and mHoxb6 (n=38/96) (g) compared 
to +2.0drl:EGFP (n=9/25) (h), revealing axial mesoderm expression of the tested mouse enhancers. Asterisks point out axial mesoderm expression. Scale 
bar (b-d) 250 μm, (e-h) 200 μm. 
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Supplementary Figure 9: Examples of electroporated chicken embryos with +2.0drl reporters driving specific expression in the chicken LPM 
(a) Posterior region of chicken embryo represented in a schematic showing different territories. (b-f) Ex ovo cultured chicken embryos electroporated with 
+2.0drl cis-regulatory reporters as (b-c) +2.0drl:EGFP, (d-f) +2.0drl:mCherry (magenta) together with control plasmid (b-c) pCAGGS:RFP (magenta) or (d-
g) pCAGGS:EGFP at HH3+/HH4. Arrowheads indicate extra-embryonic endothelial/blood progenitors and asterisks the heart field (f). The dashed lines 
indicate the outline of the chicken embryos based on bright field imaging, with anterior (a) located to the left. 
(g) Schematic and (h,i) confocal Z-stack projections of a transverse section through the trunk region of the transgenic +2.0drl:EGFP and (j) negative control 
(uninjected) embryo counterstained with fibronectin antibody at tailbud stage 32, showing mesendoderm (arrowheads) and endodermal EGFP positive cells. 
(k) Schematic and (l,m) confocal Z-stack projections of transverse sections through the trunk region of the transgenic +2.0drl:EGFP and (n) negative control 
(uninjected) animals at stage 43 showing EGFP positive cells in the gut lining (arrowheads) consistent with LPM origin, and a few cells in the endoderm. 
Scale bars (b-f) 250 µm, (h-i, l-n) 200 µm. 
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Supplementary Figure 10
Supplementary Figure 10: +2.0drl drives specific reporter expression in lamprey, Ciona, and amphioxus 
(a-d) Whole-mount ISH for pmHandA marks the LPM in lamprey embryos from neurula to hatching stages (st 18-25). (a) Expression is first detectable as 
bilateral stripes in the PLPM at st 18. (b,c) Later, the PLPM expression expands covering the yolk, and pmHandA is upregulated in the heart tube, branchial 
region, and caudal to the heart. Lateral and dorsal views are shown with the anterior (a) of the embryo to the left. (i-k) Transverse sections of fixed st 21-22 
embryos. The schematics indicate the plane of sectioning in blue and sections are shown with dorsal to the top. The schematic transverse section 
represents k-III. (i) ISH for pmHandA at st 21 marking the LPM (black arrowheads). (j,k) ISH for EGFP in transverse sections of +2.0drl:EGFP transient 
transgenic lamprey embryos fixed at st 21-22, showing enhancer activity in the anterior mesendoderm subjacent to the ectoderm (black arrowheads), in the 
pharyngeal endoderm (k-III, white arrowhead), in the pharyngeal mesoderm (k, black arrowheads), and in some embryos in the ectoderm as commonly 
observed unspecific expression of reporter plasmids (k-II, black arrowheads). (l,m) Immunostaining for EGFP in Ciona larvae embryo (st 26) expressing drl 
reporters (green) and Mesp:H2B-mCherry to track the B7.5 nuclei cell lineage (red). (L) Expression of +2.0drl-driven EGFP reporter in the larvae is stained 
in the mesenchymal lineage (white asterisks) and in the B7.5 cell progeny including ASM precursors (ASMP) (white arrow) and both cardiac first and second 
heart precursors (FHPs and SHPs) (white arrowheads), zoomed in box. Anterior to the left. (m) Proportion of larvae embryos expressing both GFP and 
mCherry in the B7.5 lineage when co-electroporated drl reporter and Mesp:H2B-mCherry in comparison to the control. N = number of electroporated larval 
halves. (n-p) Confocal Z-stack of amphioxus embryo at mid-neurula stage (6/7 ss), injected with +2.0drl:EGFP, showing specific reporter activity in the 
lateral endoderm (arrowhead), and ventral half of the somites (n=61/65, arrows). Embryos counterstained with Phalloidin (red), embryos/larvae with DAPI 
(blue), and anti-acetylated tubulin antibody (magenta). Lateral view shown as 3D-rendering (n) or Z-stack sagittal sections (o), anterior to the left and dorsal 
to the top. At early larvae stage (p), the activity of +2.0drl reporter was observed in the developing pharynx (n=15/30, arrowhead). Branchial region (br), 
heart (h), neural folds (nf), neural tube (nt), notochord (n), pharynx (ph), and yolk (y) labeled (i-k). Scale bars (i-k) 200 µm, (l) 25 µm, (n,p) 50 µm. 
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 Transgene cloning 
 The transgene vectors -1.0drl:EGFP (pDestTol2pA2_-1.0drl:EGFP) and [proximal]drl:EGFP 
(pDestTol2pA2_[proximal]drl:EGFP) were assembled from pENTR/5’_-1.0drl or pENTR/5’_[proximal]drl 
together with Tol2kit vectors #383 (pME-EGFP), #302 (p3E_SV40polyA), and #394 (pDestTol2A2) as 
backbone. +2.0drl:EGFP (pDestTol2pA2_+2.0drl:EGFP) and +2.4drl:EGFP (pDestTol2pA2_ 
+2.4drl:EGFP) were assembled from pENTR/5’_+2.0drl or pENTR/5’_+2.4drl together with pME-β-
globin_minpromoter_EGFP1, Tol2kit vectors #302 (p3E_SV40polyA), and #394 (pDestTol2A2) as 
backbone2. +2.0drl:creERT2 (pDestTol2CY_+2.0drl:creERT2,alpha-crystallin:YFP) and -
5.0sox17:creERT2 (pDestTol2CY_-5.0sox17:creERT2,alpha-crystallin:YFP) were assembled from 
pENTR/5’_+2.0drl or pENTR/5’_-5.0sox17 together with pCM293 (pENTR/D_creERT2)3, Tol2kit vector 
#302 (p3E_SV40polyA), and pCM326 (pDestTol2CY) as backbone4. Genomic coordinates for the 
+2.0drl enhancer used in the described constructs are chr5:61,649,227-61,650,194 
(GRCz11/danRer11). Transcription factor binding sites were predicted using the JASPAR online 
interface5. Synteny analysis was performed using the Genomicus web server6. 
 The regulatory elements of mouse-specific LPM enhancers were PCR-amplified (Supplementary Table 
1; regulatory elements), TOPO-cloned into the pENTR5' plasmid, and assembled together with pKD001 
(pME-β-globin_minpromoter_EGFP with improved Kozak sequence), Tol2kit vectors #302 
(p3E_SV40polyA), and #394 (pDestTol2A2) as backbone. 
Assembled reporter constructs were injected at a concentration of 25 ng/μl together with 25 ng/μl Tol2 
mRNA for Tol2-mediated zebrafish transgenesis. Injected F0 founders were screened for specific EGFP 
or alpha-crystallin:YFP expression. Zebrafish were raised to adulthood and screened in F1 for germline 
transmission. Single-insertion transgenic strains were generated, and microscopy images were taken on 
a Leica M205FA with a Leica DFC450C digital camera or a Leica SP8 confocal microscope with Plan-
Apochromat 20x/0.5 objective. Images were processed using Leica LAS and Fiji7. 
 
Zebrafish strains 
Established transgenic and mutant lines used in this study included drl:EGFP4, drl:mCherryzh705 (Ref. 
8), drl:creERT24, ubi:creERT23, ubi:switch3, hsp70l:Switchzh701 (Ref. 9), lmo2:dsRED210, scl/tal1:EGFP11, 
pax2.1:EGFP12, hand2:EGFP13, actb2:h2afva-mCherry14, maternal and zygotic EGF-CFC co-receptor 
oep gene mutants (MZoep)15, and maternal-zygotic somitabundtc24 mutants (sbn, dominant-negative 
smad5)16,17. 
 
Zebrafish CreERT2-based lineage tracing 
 Lineage tracing experiments were performed by crossing female hsp70l:Switch9 or ubi:Switch3 reporter 
carriers with the male creERT2 drivers drl:creERT24, sox17:creERT2, and +2.0drl:creERT2. Embryos 
were induced using 4-Hydroxytamoxifen (4-OHT) (H7904; Sigma H7904) from fresh or pre-heated (65°C 
for 10 min) stock solutions in DMSO at a final concentration of 10 μM in E3 embryo medium at indicated 
time points. Embryos were washed in untreated E3 medium at 24 hpf. To induce EGFP transcription in 
hsp70l:Switch carrying embryos, the embryos were incubated at 37°C for 1 hour, 2-3 hours before 
fixation. Embryos were fixed with 4% paraformaldehyde (PFA) overnight at 4°C at 3 dpf and processed 
for confocal analysis.  
 
Zebrafish morpholino and crispant experiments 
 The previously established and validated sox32 morpholino18 was synthesized by GeneTools 
(sequence: 5’-TGCTTTGTCATGCTGATGTAGTGGG-3’) and dissolved in nuclease-free water to a stock 
concentration of 10 µg/µl. The sox32 morpholino injection mix of 4 µg/µl was incubated for 10 min at 
65°C, and 8 ng were microinjected into one-cell stage zebrafish embryos. 
 sgRNAs were obtained in an oligo-based approach19. Primer extension was performed using Phusion 
polymerase (NEB) of forward primer 5’-GAAATTAATACGACTCACTATAGG-N20-
GTTTTAGAGCTAGAAATAGC-3’ (including a 20 nt target site) and invariant reverse primer 5’- 
AAAAGCACCGACTCGGTGCCACTTTTTCAAGTTGATAACGGACTAGCCTTATTTTAACTTGCTATTTC
TAGCTCTAAAAC-3’ (PAGE-purified). The following target sites are shown in this manuscript: 5’-
AGATTTGTTTAGTCAGTGTC-3’ (drl ccG), 5’-GTCTGGAAACAGTCTGAATC-3’ (drl ccH), 5’-
GAGACTTCGCCCTTCGGTTC-3’ (mixl1 ccB), and 5’-GACAGAACAGGCCACGTTGA-3’ (mezzo ccA). 
 In vitro transcription of sgRNAs was performed using MAXIscript T7 (Ambion). Afterwards, RNA was 
precipitated with ammonium acetate, washed with 75% ethanol, and dissolved in DEPC water. RNA 
quality was checked on a MOPS gel. RNPs of Cas9 protein (Cas9-mCherry, pMJ29319; available from 
Addgene) and sgRNA were in vitro-assembled for 10 min at 37°C in 300 mM KCl to ensure maximum 
cleavage efficiency and microinjected into the cell of one-cell stage embryos19. The CRISPR target 
regions in the transgenic locus were amplified using specific target region amplification primers 
(Supplementary Table 1; target region amplifications). 
 Sequencing analysis was performed with the R software package CrispRVariants for allele- and 
sequence-level variant counting and visualization20.  
 
Zebrafish overexpression experiments   
 For early developmental transcription factor genes, ORFs were PCR-amplified from mixed-stage 
zebrafish cDNA using ORF-specific primers (Supplementary Table 1; coding sequence primers); full-
length zebrafish eomesA was derived from I.M.A.G.E clone IRBOp991A0739D (Source BioScience 
LifeSciences, UK). All CDS were TOPO-cloned into the pENTR/D™ Directional TOPO® plasmid 
(Invitrogen) according to the manufacturer’s instructions. Constitutive-active Smad2, which encodes an 
N-terminal truncation of zebrafish Smad221, was amplified from zebrafish cDNA and subcloned into 
pENTR1A (pCM269). Subsequent cloning reactions were performed with the Multisite Gateway system 
with LR Clonase II Plus (Invitrogen) according to the manufacturer’s instructions. The CDS as pENTR/D 
vectors (pENTR1A for smad2(ca)) were assembled with pENTR5'_ubi3, pENTR5'_T7-VP16, 
pENTR5'_T7-eng or pENTR5'_T7 together with Tol2kit vectors #302 (p3E_SV40polyA), and #394 
(pDestTol2A2) as backbone2. Afterwards, plasmids were linearized (in case of T7-VP16, T7-eng, or T7) 
and in vitro transcribed (Roche). The EomesA-VP16 plasmid (containing 153aa-431aa of the zebrafish 
EomesA ORF)22 was kindly provided by Dr. Rebecca Burdine. The plasmid was linearized via NotI 
followed by SP6 in vitro transcription. All mRNAs were precipitated with ammonium acetate, washed with 
75% ethanol, and dissolved in DEPC water. mRNA quality was checked on MOPS gels. 
 
 
 
 
  
Supplementary Table 1: Primer sequences 
 
Regulatory elements  
 
-1.0drl   zebrafish 
 
5’-TTTCAATTTCAAAGGAGC-3’  
 
 
[proximal]drl  zebrafish 
 
5’-TGTTTTGAGTGAGTCGGTTAGG-3’ 
 
5’- CTGTCATCATTCACTCACCC-3’  
5’-CAACTGGGACATATTTAAACC-3’   
 
+2.0drl zebrafish 5’-CACTTCCTAATCTGCTATTGCC-3’  
 
 
+2.0drl  
for lamprey expression 
 
+2.0drl 
for Ciona expression 
 
+2.4drl:EGFP zebrafish 
 
 
+2.4drl:EGFP  
for lamprey expression 
 
 
+2.4drl:EGFP  
for Ciona expression 
 
-5.0sox17 
 
 
mBmp4 
 
 
mHoxb6 
 
 
mGata4 
5’-CCAAGTGTGAATTGGGATCG-3’   
 
5’-CCCTCGAGGTCGACGCACTTCCTAATCTGCTATTG-3’ 
5’- GAGGATATCGAGCTCGCCAAGTGTGAATTGGGATC-3’ 
 
5’-CTCGAGCACTTCCTAATCTGCTATTGCC-3’  (w/ Xho1) 
5’-TCTAGACCAAGTGTGAATTGGGATCG-3’  (w/ Xba1) 
 
5’-GTCAAATCAATCAATGCGGTGC-3’  
5’-CCAAAGACAATTAAACCACC-3’  
 
5’-AGGGTAATGAGGGCCGTCAAATCAATCAATGCGGTGCTC-3’ 
5’GAGGATATCGAGCTCGCCAAAGACAATTAAACCACCAGATTCAG-3’  
 
5’-CTCGAGGTCAAATCAATCAATGCGG-3’  (w/ Xho1) 
5’-TCTAGACCAAAGACAATTAAACCACC-3’  (w/ Xba1) 
 
5’-TGACGACCCCCAGGTCAACC-3’ 
5’-CTCAAACACGCACCGGGC-3’  
 
5’-GGGGATGAAAGTAGCATCCTG-3’ 
5’-TTCCACTTTGCTTCCCAAACTGG-3’  
 
5’-AATGGAGAACTGGCTGGTG-3 
5’-ATCCTTTAGAGCAGCAACCC-3’  
 
5’-CCTTCCTATACACGCTTGC-3’  
5’-TCCTTCCCAAGCCCTGAGG-3’  
 
 
 
Target region amplification   
 
drl 
 
5’-AATCACAAAGTCTGGGTTAACAGAG-3’  
 
 
mixl1 
 
 
mezzo 
 
5’-CGACCAGGATGGGCACCAC-3’ (EGFP region) 
 
5’-GGCTGCTGTTATCAGTCTC-3’  
5’-GGGATGGTGGTTGGGTCG-3’ 
 
5’-CGCTGTGGCGACCTCTGA-3’ 
5’-CTTGCTCTCTGGAAGCAGCG-3’  
  
Coding sequences  
 
foxh1 
 
5’-CACCATGACAAAGCACTGGGGG-3’ 
 
 
mixl1 
5’-TTAAAGAGAATATTTGCAAAGG-3’ 
 
5’-CACCATGGCAGTCGTGCACGGAAACC-3’  
5’-CTAAATGAAGCCATTAAAACC-3’  
 
 
 
in situ hybridization  
 
EGFP 
 
5’-ATGGTGAGCAAGGGCGAGGAGC-3’  
 
 
drl 
 
 
hand2 
 
 
foxf1 
 
 
ved 
 
 
tmem88a 
5’-TAATACGACTCACTATAGGG-3’ 
 
5’-ATGAAGAATACAACAAAACCC-3’ 
5’-TAATACGACTCACTATAGGTGAGAAGCTCTGGCCGC-3’ 
 
5’-CACCATGAGTTTAGTTGGAGGGTTTCC-3’ 
5’-TAATACGACTCACTATAGGGTCATTGCTTCAGTTCCAATGCC-3’ 
 
5’-ATACCGCGCTATCATACC-3’ 
5’-GAATTCTAATACGACTCACTATAGGGAAAGCAGTCTTAACTCTGG-3’ 
 
5’-CACCATGAAGGGTCAGTTCTCC-3’ 
5’-TAATACGACTCACTATAGGGCACAATAAAGCCAGTCC-3’  
 
5’-ATGAGTCTTCCACGAAACGG-3’ 
5’-TAATACGACTCACTATAGGGATGAAGCACAGGCCC-3’ 
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